1. Issues Affecting ART Success: Adherence, ARV Toxicity, Drug Interactions Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents December 2009 AETC NRC Slide Set

2. December 2009 2 www.aidsetc.org These slides were developed using the December 2009 guidelines. The intended audience is clinicians involved in the care of patients with HIV. Because the field of HIV care is rapidly changing, users are cautioned that the information in this presentation may become out of date quickly. It is intended that these slides be used as prepared, without changes in either content or attribution. Users are asked to honor this intent. – AETC NRC http://www.aidsetc.org About This Presentation

3. December 2009 3 www.aidsetc.org Initiation of Therapy: Contents  Adherence  ARV-associated adverse effects  Drug interactions

4. December 2009 4 www.aidsetc.org Adherence  High adherence rates associated with virologic suppression, low rates of resistance, and improved survival  Important to assess readiness for ART prior to initiating therapy, and to assess adherence at each clinic visit  Suboptimal adherence is common

5. December 2009 5 www.aidsetc.org Predictors of Inadequate Adherence  Regimen complexity and pill burden  Low literacy level  Active drug use or alcoholism  Stigma  Mental illness (especially depression)  Cognitive impairment  Lack of patient education  Medication adverse effects  Treatment fatigue

6. December 2009 6 www.aidsetc.org Predictors of Inadequate Adherence (2)  Age, race, sex, educational level, socioeconomic status, and a past history of alcoholism or drug use do NOT reliably predict suboptimal adherence  Higher socioeconomic status and education levels and lack of history of drug use do NOT reliably predict optimal adherence

7. December 2009 7 www.aidsetc.org Measurement of Adherence  No gold standard  Patient self-report overestimates adherence, but is associated with viral load responses and is most useful method in the clinic setting  Self-report of suboptimal adherence is strong indicator of nonadherence

8. December 2009 8 www.aidsetc.org Predictors of Good Adherence  Emotional and practical supports  Convenience of regimen  Understanding of the importance of adherence  Belief in efficacy of medications  Feeling comfortable taking medications in front of others  Keeping clinic appointments  Severity of symptoms or illness

9. December 2009 9 www.aidsetc.org Improving Adherence  Establish readiness to start therapy  Provide education on medication dosing  Review potential side effects  Anticipate and treat side effects  Use educational aids including pictures, pillboxes, and calendars

10. December 2009 10 www.aidsetc.org Improving Adherence (2)  Simplify regimens, dosing, and food requirements  Engage family, friends  Utilize team approach with nurses, pharmacists, and peer counselors  Provide accessible, trusting health care team

11. December 2009 11 www.aidsetc.org ART-Associated Adverse Effects  Lactic acidosis/hepatic steatosis  Hepatotoxicity  Insulin resistance, diabetes melitis  Fat maldistribution  Hyperlipidemia  Cardiovascular and cerebrovascular effects  Increased bleeding in hemophiliacs  Osteonecrosis, osteopenia, osteoporosis  Rash

12. December 2009 12 www.aidsetc.org Adverse Effects: NRTIs  All NRTIs:  Lactic acidosis and hepatic steatosis (highest incidence with d4T, then ddI and ZDV, lower with TDF, ABC, 3TC, and FTC)  Lipodystrophy (higher incidence with d4T)

13. December 2009 13 www.aidsetc.org Adverse Effects: NRTIs (2)  ABC  HSR*  Rash  Possible ↑ risk of MI  ddI  GI intolerance  Peripheral neuropathy  Pancreatitis  Possible noncirrhotic portal hypertension * Screen for HLA-B*5709 before treatment with ABC; ABC should not be given to patients who test positive for HLA-B*5709.

14. December 2009 14 www.aidsetc.org Adverse Effects: NRTIs (3)  d4T  Peripheral neuropathy  Pancreatitis  TDF  Renal impairment  Possible decrease in bone mineral density  Headache  GI intolerance  ZDV  Headache  GI intolerance  Bone marrow suppression

15. December 2009 15 www.aidsetc.org Adverse Effects: NNRTIs  All NNRTIs:  Rash, including Stevens-Johnson syndrome  Drug-drug interactions  EFV  Neuropsychiatric  Teratogenic in nonhuman primates + cases of neural tube defects in human infants after 1st-trimester exposure  NVP  Higher rate of rash  Hepatotoxicity (may be severe and life-threatening; risk higher in patients with higher CD4 counts at the time they start NVP)

16. December 2009 16 www.aidsetc.org Adverse Effects: PIs  All PIs:  Hyperlipidemia  Insulin resistance and diabetes  Lipodystrophy  Elevated LFTs  Possible increased risk of MI and CVA  Possibility of increased bleeding risk for hemophiliacs  Drug-drug interactions

17. December 2009 17 www.aidsetc.org Adverse Effects: PIs (2)  ATV  Hyperbilirubinemia  PR prolongation  Nephrolithiasis  DRV  Rash  Liver toxicity  FPV  GI intolerance  Rash  Possible increased risk of MI

18. December 2009 18 www.aidsetc.org Adverse Effects: PIs (3)  IDV  Nephrolithiasis  GI intolerance  LPV/r  GI intolerance  Possible increased risk of MI  PR and QT prolongation  NFV  Diarrhea

19. December 2009 19 www.aidsetc.org Adverse Effects: PIs (4)  RTV  GI intolerance  Hepatitis  SQV  GI intolerance  TPV  GI intolerance  Rash  Hyperlipidemia  Liver toxicity  Cases of intracranial hemorrhage

20. December 2009 20 www.aidsetc.org Adverse Effects: II  RAL  Nausea  Headache  Diarrhea  CPK elevation

21. December 2009 21 www.aidsetc.org Adverse Effects: Fusion Inhibitor  ENF  Injection-site reactions  HSR  Increased risk of bacterial pneumonia

22. December 2009 22 www.aidsetc.org Adverse Effects: CCR5 Antagonist  MVC  Drug-drug interactions  Abdominal pain  Upper respiratory tract infections  Cough  Hepatotoxicity  Musculoskeletal symptoms  Rash  Orthostatic hypotension

23. December 2009 23 www.aidsetc.org ARV-Associated Adverse Effects: Lactic Acidosis/Hepatic Steatosis  Rare, but high mortality  Evidently due to mitochondrial toxicity  Associated with NRTIs (especially d4T, ddI, ZDV)  More common in women, pregnancy, obesity  Clinical presentation variable: have high index of suspicion  Lactate >2-5 mmol/dL plus symptoms  Treatment: discontinue ARVs, supportive care

24. December 2009 24 www.aidsetc.org ARV-Associated Adverse Effects: Hepatotoxicity  Severity variable: usually asymptomatic, may resolve without treatment interruption  May occur with any NNRTI or PI, most NRTIs, or MVC:  NVP: risk of severe hepatitis in first 18 weeks of use (monitor LFTs closely), increased risk in chronic hepatitis B and C, women, and high CD4 count at initiation of NVP (>250 cells/µL in women, >400 cells/µL in men)  PIs: especially RTV, TPV, perhaps DRV; increased risk in hepatitis B or C, ETOH, other hepatotoxins

25. December 2009 25 www.aidsetc.org ARV-Associated Adverse Effects: Insulin Resistance, Diabetes  Insulin resistance, hyperglycemia, and diabetes associated with ZDV, d4T, some PIs, especially with chronic use  Mechanism not well understood  Insulin resistance, relative insulin deficiency  Screen regularly: fasting glucose

26. December 2009 26 www.aidsetc.org ARV-Associated Adverse Effects: Fat Maldistribution Lipodystrophy:  No uniform definition  Mechanism not well understood  Peripheral fat wasting more associated with NRTIs, especially thymidine analogues (d4T>ZDV, ddI>TDF, ABC, 3TC, FTC)  Central fat accumulation perhaps more associated with PIs, especially if used with thymidine analogues  May be associated with dyslipidemia, insulin resistance, lactic acidosis  Monitor closely; intervene early  Treatment: switching to other agents may slow or halt progression

27. December 2009 27 www.aidsetc.org ARV-Associated Adverse Effects: Hyperlipidemia  Elevations in total cholesterol, LDL, and triglycerides  Elevation in HDL seen with some RTV-boosted PIs  Associated with all PIs (except ATV), d4T, EFV, NVP  Mechanism unknown  Concern for cardiovascular events, pancreatitis  Monitor regularly  Treatment: consider ARV switch; lipid-lowering agents (caution with PI + certain statins)

28. December 2009 28 www.aidsetc.org ARV-Associated Adverse Effects: Cardiovascular and Cerebrovascular Effects  Increased risk of MI and CVA associated with PIs  Increased risk of MI associated with recent ABC use in some studies (data are not consistent)  Seen especially in patients with traditional cardiovascular risk factors  Assess and manage cardiovascular risk factors  Consider ARVs with less risk of cardiovascular events, especially in patients at high risk of cardiovascular disease

29. December 2009 29 www.aidsetc.org ARV-Associated Adverse Effects: Bone Abnormalities  Osteonecrosis (AVN)  Mechanism unknown  Associated with PIs; unclear whether caused by them  Other risk factors: corticosteroid treatment, alcohol abuse, hemoglobinopathies, hyperlipidemia, hypercoagulable states  Treatment: surgical treatment for severe disease  Osteopenia  Associated with various ARVs, particularly TDF, d4T  Other risk factors: low body weight, female, white or Asian, older age, alcohol or tobacco use, hypogonadism, vitamin D deficiency, corticosteroid exposure  Consider assessment by DEXA  Management: calcium + vitamin D, bisphosphonate, weight- bearing exercise, hormone replacement

30. December 2009 30 www.aidsetc.org ARV-Associated Adverse Effects: Rash  Most common with NNRTIs, especially NVP  Most cases mild to moderate, occurring in first 6 weeks of therapy; occasionally serious (eg, Stevens-Johnson syndrome)  No benefit of prophylactic steroids or antihistamines (increased risk with steroids)  NRTIs: especially ABC (consider hypersensitivity syndrome)  PIs: especially FPV, DRV, TPV  CCR5 antagonist: MVC

31. December 2009 31 www.aidsetc.org ARV-Associated Adverse Effects: Nephrotoxicity  Associated with IDV, TDF  IDV: increased Cr, pyuria, hydronephrosis or renal atrophy  TDF: increased Cr, proteinuria, hypophosphatemia, hypokalemia, proteinuria  Increased risk in patients with renal disease, low CD4 count  Monitor Cr, other renal parameters  Management: stop the offending ARV + supportive care

32. December 2009 32 www.aidsetc.org Overlapping Toxicities  Peripheral neuropathy  ddI, d4T, ddC, isoniazid  Bone marrow suppression  ZDV, dapsone, hydroxyurea, ribavirin, TMP-SMZ  Hepatotoxicity  NVP, EFV, MVC, NRTIs, PIs, macrolides, isoniazid  Pancreatitis  ddI, RTV, d4T, TMP-SMZ, pentamidine

33. December 2009 33 www.aidsetc.org Drug Interactions with ARVs  Certain ARVs, particularly PIs and NNRTIs, have significant drug interactions with other ARVs and with other medications  Interactions may be complex and difficult to predict  Coadministration of some ARVs with other ARV or non-ARV medications may require dose adjustment, and some combinations may be contraindicated  Check for interactions before prescribing

34. December 2009 34 www.aidsetc.org Drug Interactions with ARVs  Increases in serum drug levels caused by inhibitors of metabolism may increase risk of medication toxicity, while decreases in drug levels caused by inducers of metabolism may cause treatment failure  Some drug interactions may be exploited, eg, low- dose ritonavir (a strong CYP3A4 inhibitor) may be used as a pharmacokinetic enhancer to increase concentrations and prolong the half-life of other PIs

35. December 2009 35 www.aidsetc.org Drug Interactions with ARVs  All PIs and NNRTIs are metabolized by the hepatic CYP 450 system, particularly the CYP3A4  PIs  All PIs are CYP3A4 substrates, and their serum levels may be affected by CYP inducers or inhibitors  Some PIs also are inducers or inhibitors of other CYP isoenzymes or of P-glycoprotein (PGP) or other transporters  NNRTIs  Substrates of CYP3A4, can act as inducer (NVP) or mixed inducer and inhibitor (EFV)  ETR is substrate of 3A4, 2C9, and 2C19; and inhibitor of 2C9 and 2C19

36. December 2009 36 www.aidsetc.org Drug Interactions with ARVs  NRTIs  No hepatic metabolism, but some NRTIs may interact via other mechanisms (eg, decrease in ATV concentration if coadministered with TDF, proton pump inhibitors, H2 receptor antagonists)  Integrase inhibitor  RAL: eliminated by glucuronidation; inducers of UGT1A1 (eg, rifampin) can reduce RAL concentration

37. December 2009 37 www.aidsetc.org Drug Interactions with ARVs  CCR5 antagonist  MVC: substrate of CYP3A and PGP; concentrations are significantly affected by CYP3A inhibitors or inducers. Dosage adjustment necessary.  Fusion inhibitor  ENF: no known significant drug interactions

38. December 2009 38 www.aidsetc.org Common Drug Interactions with ARVs: Require Dosage Modification or Cautious Use  Lipid-lowering agents  Antimycobacterials, especially rifampin*  Antifungals  Psychotropics – midazolam, triazolam  Ergot alkaloids  Antihistamines – astemizole  Anticonvulsants * Of NNRTIs and PIs, rifampin may be used only with full- dose RTV or with EFV.

39. December 2009 39 www.aidsetc.org Common Drug Interactions with ARVs: Require Dosage Modification or Cautious Use (2)  Oral contraceptives (may require second method)  Methadone  Erectile dysfunction agents  Herbs – St. John’s wort

40. December 2009 40 www.aidsetc.org ARV-ARV Interactions: Require Dosage Modification or Cautious Use  EFV, NVP, or ETR with PIs  ATV + TDF  ddI + TDF  ddI + d4T  MVC + many PIs  MVC + EFV or ETR

41. December 2009 41 www.aidsetc.org ARV-ARV Interactions  Interactions involving ARVs often require dose adjustment of the ARV and/or the interacting medication  Some combinations are contraindicated  Consider the possibility of interactions whenever adding a new medication  Consult with expert pharmacists or clinicians

42. December 2009 42 www.aidsetc.org Websites to Access the Guidelines  http://www.aidsetc.org  http://aidsinfo.nih.gov

43. December 2009 43 www.aidsetc.org  This presentation was prepared by Susa Coffey, MD, for the AETC National Resource Center in December 2009.  See the AETC NRC website for the most current version of this presentation: http://www.aidsetc.org About This Slide Set